Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©

Patient. 2017 Jun;10(3):321-334. doi: 10.1007/s40271-016-0211-y.

Abstract

Introduction: The National Lipid Association Statin Intolerance (SI) Panel recognized the need for better understanding of the patient SI experience.

Objective: The objective of this research was to develop a patient-reported outcome (PRO) questionnaire to assess a patient's experience with SI.

Methods: Questionnaire development was informed via a series of research activities: literature review, concept elicitation, item generation, and content evaluation. Following the literature review and concept elicitation, a draft questionnaire was constructed and subsequently modified based on feedback from therapeutic area experts and patients via cognitive debriefing interviews.

Results: Muscle-related symptoms were the most commonly reported symptoms associated with SI in the literature review (35 of 41 articles reviewed [85%]) and in semi-structured interviews with experts (n = 5 [100%]) and patients (n = 17 of 20 [85.0%]). Physical and other impacts of SI symptoms on daily activities were also frequently reported. A 17-item draft questionnaire was created, and cognitive debriefing with experts (n = 5) and patients (n = 15) was conducted. Overall, the items, response options, and instructions were comprehensible and positively reviewed; minor changes resulted in the 15-item Statin Experience Assessment Questionnaire (SEAQ)©. Using a 30-day recall period, the SEAQ© assesses the severity and impact of six SI symptoms (muscle ache, muscle pain, muscle cramps, muscle weakness, tiredness, and joint pain) on an 11-point numeric scale. Statin discontinuation and likelihood of discontinuation due to symptoms are assessed and scored on a yes/no and five-point verbal response scale, respectively.

Conclusion: The SEAQ

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Arthralgia / chemically induced*
  • Arthralgia / psychology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Male
  • Middle Aged
  • Muscular Diseases / chemically induced*
  • Muscular Diseases / psychology
  • Patient Reported Outcome Measures
  • Psychometrics
  • Reproducibility of Results
  • Severity of Illness Index
  • Surveys and Questionnaires / standards*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors